Staging Systems (BCLC 2024) for Liver Cancer
Updated Barcelona Clinic Liver Cancer staging system for hepatocellular carcinoma prognosis and treatment allocation.
BCLC 2024 Staging System Overview
The gold standard for HCC management integrating tumor burden, liver function, and performance status.
The Barcelona Clinic Liver Cancer (BCLC) staging system, updated in 2024, remains the most widely adopted framework for hepatocellular carcinoma (HCC) prognostication and treatment allocation. It classifies patients into six stages (0, A, B, C, D) based on tumor characteristics, liver function (Child-Pugh score), and performance status (ECOG).
BCLC 2024 incorporates new evidence on systemic therapies, immunotherapy combinations, and downstaging strategies while maintaining its core prognostic variables.
Key Updates in BCLC 2024
Stage B refinement: Subclassification into B1, B2, B3 based on tumor burden
Immunotherapy integration: First-line atezolizumab-bevacizumab for Stage C
Downstaging criteria: Expanded eligibility for curative therapies
Performance status: ECOG 0-2 for systemic therapy
BCLC 2024 Stages & Treatment Recommendations
Detailed classification with median survival and evidence-based therapies
Stage 0 (Very Early)
Single tumor ≤2 cm, preserved liver function
- Child-Pugh A
- ECOG 0
- Median survival: >5 years
- Treatment: Resection or ablation
Stage A (Early)
Single tumor or ≤3 nodules ≤3 cm
- Child-Pugh A-B
- ECOG 0
- Median survival: 3-5 years
- Treatment: Resection, ablation, transplant
Stage B (Intermediate)
Multinodular tumors, preserved liver function
- Child-Pugh A-B
- ECOG 0
- Substages B1-B3
- Treatment: TACE, systemic therapy
Stage C (Advanced)
Vascular invasion or extrahepatic spread
- Child-Pugh A-B
- ECOG 0-2
- Median survival: 11-13 months
- Treatment: Atezolizumab + Bevacizumab
Stage D (Terminal)
Severe liver dysfunction
- Child-Pugh C
- ECOG 3-4
- Median survival: <3 months
- Treatment: Best supportive care
BCLC 2024 Classification Table
| Stage | Tumor Characteristics | Liver Function | Performance Status | First-Line Treatment | Median Survival |
|---|---|---|---|---|---|
| 0 | Single ≤2 cm | Child-Pugh A | ECOG 0 | Resection/Ablation | >60 months |
| A | Single or ≤3 nodules ≤3 cm | Child-Pugh A-B | ECOG 0 | Transplant/Resection | 36-60 months |
| B | Multinodular | Child-Pugh A-B | ECOG 0 | TACE/Systemic | 20-36 months |
| C | Portal invasion/Extrahepatic | Child-Pugh A-B | ECOG 0-2 | Atezo+Bev | 11-13 months |
| D | Any | Child-Pugh C | ECOG 3-4 | Supportive care | <3 months |
Prognostic Factors in BCLC 2024
Tumor burden: Number, size, vascular invasion
Liver function: Child-Pugh score, albumin-bilirubin grade
Performance status: ECOG scale
Extrahepatic spread: Lymph nodes, distant metastasis
BCLC 2024 Treatment Algorithm
Evidence-based therapeutic strategy by stage
Curative Intent (Stages 0-A)
Resection: Solitary tumors, no portal hypertension
Ablation: RFA/MWA for ≤3 cm lesions
Transplantation: Milan criteria or downstaged patients
Locoregional Therapy (Stage B)
TACE: Conventional or DEB-TACE
TARE: Y90 radioembolization for large/multifocal
Systemic therapy: For TACE-refractory cases
Systemic Therapy (Stage C)
First-line: Atezolizumab + Bevacizumab
Alternative: Durvalumab + Tremelimumab
Second-line: Sorafenib, Lenvatinib, Cabozantinib
Palliative Care (Stage D)
Symptom management, nutritional support, end-of-life care
Scientific References
Evidence-based guidelines and clinical studies supporting BCLC 2024.
- Reig, M., et al. (2024). BCLC strategy for prognosis prediction and treatment recommendation: The 2024 update. JHEP Reports.
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma (2024 update). Journal of Hepatology.
- Finn, R. S., et al. (2024). Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. NEJM.
- Llovet, J. M., et al. (2024). Immunotherapy combinations for advanced HCC. Lancet Oncology.
Need Expert Staging Evaluation?
Connect with HCC specialists for accurate BCLC staging and personalized treatment planning.